C-O-R-R-E-C-T-I-O-N
Executive Summary
C-O-R-R-E-C-T-I-O-N: Abbott's antihypertensive Hytrin (terazosin) is not yet approvable. Abbott said that it expects the final review process to begin in January, 1987. "The Pink Sheet" (Dec. 8, T&G-8) incorrectly reported that Abbott had been notified by FDA that the drug had reached the "approvable" stage.